Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Larri Oral Spray is a triple-action topical oral spray developed by ENT Technologies for the treatment of Laryngopharyngeal Reflux (LPR), also known as Silent Reflux. The formulation consists of magnesium alginate, sodium hyaluronate, and *Camellia sinensis* (green tea extract). It functions primarily as a non-pharmacological barrier; magnesium alginate creates a physical protective layer over the tissues of the laryngopharynx and oropharynx to block stomach acid and trap pepsin, while sodium hyaluronate provides lubrication and supports tissue healing. *Camellia sinensis* is included for its soothing properties on inflamed throat tissues. The product is intended to alleviate symptoms such as throat dryness, constant throat clearing, hoarseness, and dry cough associated with LPR.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Larri Oral Spray.